A method for determining the likelihood that a systemic lupus erythematosus patient will have a flare event, comprising: (a) processing a blood, serum, plasma or urine sample obtained from a patient and experimentally determining a dataset that comprises data representing protein expression level values for cytokines and molecules; (b) assessing the dataset for protein expression levels of each cytokine from each of (i), (ii), (iii), and (iv), wherein (i) are the innate type cytokines IL-1α, IL-1β, IFN-α, IFN-β, G-CSF, IL-7, and IL-15, (ii) are the Th1 type cytokines IL-2, IL-12, and IFN-γ, (iii) are the Th2 type cytokines IL-4, IL-5, and IL-13, and (iv) are the Thl7 type cytokines IL-6, IL-17A, IL-21, and IL-23, (c) assessing the dataset for protein levels of each molecule from each of (v), (vi), (vii), and (viii), wherein (v) are the chemokines/adhesion molecules IL-8, IP-10, RANTES, MCP-1, MCP-3, MIP-1α, MIP-1β, GRO-α, MIG, Eotaxin, ICAM-1, E-selectin, VCAM-1, and VEGF-A, (vi) are the TNFR superfamily member molecules TNF-α, TNFRI, TNFRII, TRAIL, Fas, FasL, BLyS, APRIL, sCD40L, and NGFβ, (vii) are the regulatory mediator molecules IL-10, TGF-β, SDF- 1, and IL-1RA, and (viii) are the SLE mediator molecules LIF, PAI-1, PDGF-BB, Leptin, SCF, Resistin and IL-2RA; and (d) determining the likelihood that the patient will have the flare event by combining the assessed data representing the protein levels to produce a score that is indicative of flare event likelihood, wherein a higher score relative to control indicates that the patient is likely to have the flare event, wherein combining the assessed data representing the protein levels to produce a score is a mathematical combination performed by an algorithm, wherein the algorithm is selected from an algorithm set forth in Figure 20, 21, 22, 23, 24, 25, 26 or, 27. (a) processing a blood, serum, plasma or urine sample obtained from a patient and experimentally determining a dataset that comprises data representing protein expression level values for cytokines and molecules; (b) assessing the dataset for protein expression levels of each cytokine from each of (i), (ii), (iii), and (iv), wherein (i) are the innate type cytokines IL-1α, IL-1β, IFN-α, IFN-β, G-CSF, IL-7, and IL-15, (ii) are the Th1 type cytokines IL-2, IL-12, and IFN-γ, (iii) are the Th2 type cytokines IL-4, IL-5, and IL-13, and (iv) are the Thl7 type cytokines IL-6, IL-17A, IL-21, and IL-23, (c) assessing the dataset for protein levels of each molecule from each of (v), (vi), (vii), and (viii), wherein (v) are the chemokines/adhesion molecules IL-8, IP-10, RANTES, MCP-1, MCP-3, MIP-1α, MIP-1β, GRO-α, MIG, Eotaxin, ICAM-1, E-selectin, VCAM-1, and VEGF-A, (vi) are the TNFR superfamily member molecules TNF-α, TNFRI, TNFRII, TRAIL, Fas, FasL, BLyS, APRIL, sCD40L, and NGFβ, (vii) are the regulatory mediator molecules IL-10, TGF-β, SDF- 1, and IL-1RA, and (viii) are the SLE mediator molecules LIF, PAI-1, PDGF-BB, Leptin, SCF, Resistin and IL-2RA; and (d) determining the likelihood that the patient will have the flare event by combining the assessed data representing the protein levels to produce a score that is indicative of flare event likelihood, wherein a higher score relative to control indicates that the patient is likely to have the flare event,